Dr. Reddy's Laboratories Limited
DRREDDY · Pharma · NSE
₹1,223
Current Market Price
Fair Value (DCF)
₹2,119
Margin of Safety
+73.3%
Updated 5h ago
YieldIQ Score
63/100
Piotroski F-Score
6/9
Economic Moat
Narrow
Confidence
45%
ROE
16.8%
Debt/Equity
0.00
WACC
9.8%
Market Cap
₹1.02 Lakh Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
22.0%
Return on capital employed
EV / EBITDA
11.3×
Enterprise multiple
Debt / EBITDA
0.7×
Leverage vs earnings
Interest Coverage
28.1×
EBIT covers interest
Current Ratio
1.92×
Short-term liquidity
Asset Turnover
0.61×
Revenue per ₹ of assets
Revenue CAGR (3Y)
—
3-year revenue growth
Revenue CAGR (5Y)
12.7%
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹1,223
Bear case
₹1,254.63
MoS +2.5%
Base case
₹2,119.28
MoS +42.3%
Bull case
₹2,913.81
MoS +58.0%
Ratio Trends
DRREDDY · last 8 annual periods
ROE
16.8%
ROCE
25.2%
Operating Margin
—
Debt / Equity
0.14×
PE
16.8×
EV / EBITDA
10.2×
Historical Financials
DRREDDY · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹19.0K Cr | ₹21.5K Cr | ₹6315 Cr | ₹5105 Cr | ₹32.6K Cr | +14.3% |
| EBITDA | — | ₹4508 Cr | ₹7443 Cr | ₹8842 Cr | ₹9667 Cr | +21.0% |
| EBIT | ₹2933 Cr | ₹3087 Cr | ₹1357 Cr | ₹1345 Cr | — | -17.7% |
| PAT | ₹1952 Cr | ₹2183 Cr | ₹960 Cr | ₹1035 Cr | ₹5654 Cr | +30.5% |
| EPS (diluted) | ₹117.34 | ₹131.21 | ₹57.68 | ₹62.04 | — | -14.7% |
| CFO | ₹3570 Cr | ₹2811 Cr | ₹5887 Cr | ₹3450 Cr | ₹4643 Cr | +6.8% |
| CapEx | — | — | — | — | ₹-3440 Cr | — |
| FCF | — | — | — | — | ₹1203 Cr | +0.0% |
| Total Assets | — | ₹29.3K Cr | ₹32.3K Cr | ₹30.4K Cr | ₹49.3K Cr | +13.9% |
| Total Debt | — | — | ₹1219 Cr | ₹710 Cr | ₹4677 Cr | +39.9% |
| Shareholders' Equity | — | — | ₹23.3K Cr | ₹24.2K Cr | ₹33.7K Cr | +9.7% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
DRREDDY vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| CIPLA CIPLA | — | — | Pending | 16.9% | 22.1× |
| LUPIN LUPIN | — | — | Pending | 19.0% | — |
| ZYDUSLIFE ZYDUSLIFE | — | — | Pending | 17.2% | — |
| MANKIND MANKIND | — | — | Pending | 13.7% | — |
| AUROPHARMA AUROPHARMA | — | — | Pending | 10.7% | — |
Click a ticker to view its fair-value analysis.
Dividend History
10 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹35.00/sh
Last payout
2025-07-10
₹8.00
Peak payout
₹8.00
Trailing yield
0.65%
Amounts parsed from NSE subject lines; percent-of-face-value declarations are not converted and shown as missing.
AI Analysis Summary
Model-generated description of metrics. Not investment advice. Dr. Reddy's Laboratories Limited (DRREDDY.NS) trades at 1223.00 vs a model fair value of 2119.28, a gap of 73.3%. Piotroski F-score: 6/9....
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of DRREDDY →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for DRREDDY →
Compare
Head-to-head with peers
Compare DRREDDY side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse DRREDDYNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.